{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://www.oxfordbiodynamics.com/#organization",
      "name": "Oxford BioDynamics PLC",
      "legalName": "Oxford BioDynamics PLC",
      "url": "https://www.oxfordbiodynamics.com/",
      "description": "Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments. The tests are based on OBD's proprietary 3D genomic biomarker platform, E"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/oxford-biodynamics-plc#asg",
      "name": "Oxford BioDynamics PLC ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/oxford-biodynamics-plc",
      "isPartOf": {
        "@id": "https://www.oxfordbiodynamics.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}